Data as-of 2026-07-17 close.

ISRG just had the single worst session in this entire scan: -14.15% in one day on nearly 4x average volume, dropping it to RSI 30.2 and -42.8% off its 52-week high — the same name last scan called "recovery stalled and reversed" just broke outright. IONS deepened further into capitulation, RSI 31.1 → 23.9, the sector's only sub-25 print. The gene-editing cohort (NTLA, CRSP, RXRX, LEGN) that unwound together last cycle kept unwinding — all four are lower again this week. Away from those extremes, the sector's cleaner large-cap cohort (AMGN, ABBV, DHR, PTGX, TMO) held up fine, still RSI 55-69 with uptrends intact.

Source: biotech-scan.json. Latest bar 2026-07-17 for every name in this cut — no stale tails today. Prior scan: 2026-07-11-biotech-scan.

The single biggest development in today's read is ISRG's collapse. The stock dropped 14.15% in one session on 3.89x its average volume, pushing RSI down to 30.2 and the price -42.8% below its 52-week high (1-day change, relative volume, and % from 52-week high per biotech-scan.json). This is the same name the July 11 scan flagged as "recovery stalled and reversed" — that reversal just turned into an outright break, and the underlying data now classifies it in a "collapse" regime rather than the "pullback" read it carried before.

IONS is the sector's other real capitulation story. RSI has fallen to 23.9, the only sub-25 print in the whole scan, down from the 31.1 flagged eleven days ago — this name has now declined for consecutive scans with no reversal signal, -26.6% over the past 30 days per the summary data.

The gene-editing cohort — NTLA, CRSP, RXRX, LEGN, EDIT — flagged last scan as "one basket, not five separate calls," kept unwinding as a group. NTLA is now RSI 30.5, CRSP 36.2, RXRX 35.3, and LEGN 27.9 — all lower than their July 11 readings. EDIT is the mild outlier at RSI 46.4.

Away from the extremes, the sector's steadier cohort held its ground. AMGN (RSI 57.5), ABBV (65.9), DHR (65.7), PTGX (69.0), and TMO (62.3, one of only five names with an "intact" thesis flag) all sit in the mid-to-high RSI range with uptrends intact and none screening as overbought.

• ISRG broke. RSI 45.0 (07-11) → 30.2 today, a -14.15% single-session drop on 3.89x average volume — the regime classifier now reads "collapse" rather than "pullback." The thesis flag is still marked "intact," which is worth revisiting.
• IONS deepened further into capitulation. RSI 31.1 → 23.9, -26.6% over the past 30 days (change30d) — the sector's only sub-25 print, still strong-down DC.
• The gene-editing cohort kept unwinding. NTLA: RSI 42.2→30.5. CRSP: 45.8→36.2. RXRX: 52.0→35.3. LEGN: 41.3→27.9. All four are worse than 07-11, continuing the group move flagged last scan.
• MRNA kept sliding. RSI 54.8→45.9, -9.45% over the past week (change7d), though still +13.24% over 3 months.
• VRTX roughly held its ground. RSI 53.1→53.4, essentially flat (change7d +0.05%) after last scan's sharp pullback.
• AMGN, ABBV, DHR, PTGX, TMO remain the sector's steadiest large caps — all still RSI 55+ with uptrends intact, none extended into overbought territory.
• Universe unchanged. Same 39 tickers as the July 11 cut — no entrants or dropouts this scan.

RSI measures how stretched a stock is over the past 14 sessions — under 30 signals oversold, over 70 signals overbought/extended. vs SMA20 is the price gap to the 20-day average; a large negative number means a fast recent decline. vs VWAP is the premium (or discount) versus the average price paid by everyone still holding — a big positive number means most of a name's move is unrealized gain that can get sold into weakness. Trend pairs direction/strength with a cross signal: GC (golden cross, the short-term average above the long-term average) is structurally healthier than DC (death cross). A stock at a low RSI while still marked strong-down DC or in a "collapse" regime — like ISRG and IONS here — is not a confirmed buy signal; it means the price is cheap relative to its own recent range, not that the structure has turned.

IONS ($54.39, RSI 23.9) — the sector's one true capitulation print, deepening from 31.1 eleven days ago, still strong-down DC with no reversal signal.

LEGN (27.9), ISRG (30.2, just crashed), NTLA (30.5), ALNY (33.9), BEAM (34.8), RXRX (35.3), CRSP (36.2), DNA (37.4). Eight names in this band, none with a confirmed trend flip — this reads as a falling-knife watch list, not a buy zone.

• Still working through a pullback (RSI 40-49): SRPT, MRNA, RARE, EDIT, BNTX. MRNA is the notable one — kept sliding this week after last scan's sharp pullback.
• Basing / cleanest accumulate (RSI 50-60): A, NKTR, LABU, BIIB, VRTX, LLY, XBI, MDT, GILD, AMGN, IBBQ, COGT, ILMN, IBB, BMRN, DXCM. AMGN remains the standout — never got extended, barely moves.
• Momentum, holding not adding (RSI 60+): REGN, TMO, IQV, NVO, KYMR, INCY, DHR, ABBV, PTGX. PTGX is the sector's most extended survivor at RSI 69.0.

• Does ISRG's crash mark a durable floor, or is there another leg down given no support shelf is identified in the data and RSI is already at 30?
• Does IONS ever stabilize, or does the sub-25 RSI keep sliding toward new lows?
• Does the gene-editing cohort (NTLA/CRSP/RXRX/LEGN) find a bottom as a group, the same way it moved together on the way up and the way down?
• Can AMGN/GILD/TMO's steady accumulate case keep holding if the rest of the sector keeps breaking down around it?

• Tape data (price/RSI/SMA/returns): full-scan pre-computed summaries as of the 2026-07-17 close — *.